Get the latest Science News and Discoveries

RFK, Jr., puts psychedelics on fast track to FDA review and approval


The U.S. Food and Drug Administration is seeking to accelerate the review process for three companies that are studying psilocybin and an MDMA-like drug as treatments for depression and PTSD

None

Get the Android app

Or read this on Scientific American

Read more on:

Photo of FDA

FDA

Photo of Psychedelics

Psychedelics

Photo of approval

approval

Related news:

News photo

RFK, Jr., praises ibogaine for depression treatment. Is the psychedelic a magic bullet?

News photo

Regeneron joins Trump to announce lower drug prices, quick FDA approval

News photo

RFK, Jr., set to overhaul key committee that issues disease screening recommendations